Search PubMed⌕ Search

Biomedical subjects

Richard Wise

Publications and source records attributed to Richard Wise.

27 records · Page 2Linked to original sources
PubMed2002

A physiological change in the homotopic cortex following left posterior temporal lobe infarction.

We investigated the relationship between cerebral activity (measured with positron emission tomography) and word rate in normal subjects and aphasic patients listening to monosyllabic words at rates up to those encountered in normal speech. By measuring the slope of the regression of the individual activity-word rate responses in the temporal cortex in normal subjects, we identified a functional asymmetry in the posterior superior temporal sulcus. The response was greater (steeper) on the left. Using the same study design, we identified a steeper activity-word rate response in the right posterior superior temporal sulcus of patients who had recovered single-word auditory comprehension after infarction of the left posterior temporal cortex. This response was significantly different from that observed in both normal subjects and a group of patients with left hemisphere infarcts that spared the posterior temporal cortex. The results demonstrated a change in physiological responsiveness in the contralateral homotopic cortex after posterior temporal infarction.

Adult↗
PubMed2002

The growth crisis--and how to escape it.

At a time when companies are poised to seize the growth opportunities of a rebounding economy, many of them, whether they know it or not, face a growth crisis. Even during the boom years of the past decade, only a small fraction of companies enjoyed consistent double-digit revenue growth. And those that did often achieved it through short-term measures--such as mergers and inflated price increases--that don't provide the foundation for growth over the long term. But there is a way out of this predicament. The authors claim that companies can achieve sustained growth by leveraging their "hidden assets," a wide array of underused, intangible capabilities and advantages that most established companies already hold. To date, much of the research on intangible assets has centered on intellectual property and brand recognition. But in this article, the authors uncover a host of other assets that can help spark growth. They identify four major categories of hidden assets: customer relationships, strategic real estate, networks, and information. And they illustrate each with an example of a company that has creatively used its hidden assets to produce new sources of revenue. Executives have spent years learning to create growth using products, facilities, and working capital. But they should really focus on mobilizing their hidden assets to serve their customers' higher-order needs--in other words, create offerings that make customers' lives easier, better, or less expensive. Making that shift in mind-set isn't easy, admit the authors, but companies that do it may not only create meaningful new value for their customers but also produce double-digit revenue and earnings growth for investors.

Commerce↗
PubMed1998

The bactericidal activity of gatifloxacin in plasma and urine.

OBJECTIVE: To investigate the bactericidal activity of gatifloxacin in serum and urine against relevant pathogens. METHODS: Serum and urine samples obtained in a single rising dose pharmacokinetic study were investigated for bactericidal activity. The doses employed were placebo, and 200, 400, 600 and 800 mg of gatifloxacin. RESULTS: The titers obtained reflected the dose and susceptibility of the pathogen. In serum a titer of greater-than-or-equal1:8 was observed for Escherichia coli for >24 h after 400 mg; for Staphylococcus aureus and Acinetobacter baumanii the titer was greater-than-or-equal1:8 for between 12--24 h after 600 mg; for Serratia marcescens it was greater-than-or-equal1:8 for >12 h following 800 mg; and for Streptococcus pneumoniae it was greater-than-or-equal1:8 for 8 h following 800 mg. In urine, the titers were greater, and for Escherichia coli, Staphylococcus saprophyticus, Proteus mirabilis and Enterococcus faecalis the titer was >1:8 for 12--24 h after 200 mg and for 24--36 h after a 400-mg dose. Pseudomonas aeruginosa demonstrated a titer of >1:8 for 18--24 h following 600 mg. CONCLUSIONS: These data suggest that gatifloxacin should be efficacious for a wide range of systemic and urinary tract infections.

Journal Article↗
PubMed1998

Grepafloxacin: pharmacokinetics and tissue penetration.

Pharmacokinetic and tissue penetration studies of grepafloxacin, a new broad-spectrum fluoroquinolone, show that it has useful properties for the treatment of respiratory tract infections. Grepafloxacin has a volume of distribution that is larger than those of many of the other fluoroquinolones and is concentrated in alveolar macrophages, bronchial mucosa and epithelial lining fluid to a greater extent than are certain other fluoroquinolones. Grepafloxacin concentrations achieved in plasma after a 400-mg oral dose are well in excess of those required to inhibit the respiratory pathogens Staphylococcus aureus, Haemophilus influenzae and Moraxella catarrhalis. Streptococcus pneumoniae is also covered for most of the dosing interval, but at normal dose levels grepafloxacin might not inhibit Enterococcus faecalis. The maximum plasma concentrations and area under the concentration---time curve achieved with grepafloxacin suggest that it will be effective for the treatment of community-acquired pneumonia and acute exacerbations of chronic bronchitis. The pharmacokinetics of fluoroquinolones are among their most useful properties. The aim of this paper is to demonstrate whether the differences between grepafloxacin and the other fluoroquinolones are of therapeutic significance.

Journal Article↗